Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms, in particular the homologous recombination pathway, for instance due to BRCA mutations. Thus, deficient DNA repair provides a framework for the success of PARP inhibitors in medical oncology. Here, we review encouraging results obtained in recent clinical trials investigating the safety and efficacy of PARP inhibitors as anticancer agents. We discuss emerging mechanisms of regulation of homologous recombination and how inhibition of DNA repair might be used in cancer therapy. We surmise that the identification of patients that are likely to benefit from PARP inhibition will improve the clinical use of PARP inhibitors in a defined target population. Thus, we will place special emphasis on biomarker discovery.
INTRODUCTION
The superfamily of poly(ADP-ribose) (PAR) polymerases (PARPs), 1 whose discovery dates back to the early 1960s, nowadays encompasses 17 distinct members that participate in a wide array of cell functions, including DNA transcription, DNA repair, genomic stability maintenance, cell cycle regulation as well as non-apoptotic cell death (Table 1) . [2] [3] [4] [5] PARP1, a multifunctional enzyme of 113 kDa, is the most abundant, ubiquitously expressed and best-characterized member of the superfamily. 6 PARP1 has a highly conserved structural and functional organization including: an N-terminal double zinc finger DNA-binding domain, a central auto-regulation domain and a C-terminal catalytic domain that binds oxidized nicotinamide adenine dinucleotide (NAD þ ). 7 PARP1 is a DNA nick sensor that utilizes NAD þ as a substrate to catalyze the covalent attachment of ADP-ribose units to the g-carboxyl group of Glu residues of a wide array of target proteins. This post-translational modification known as poly-ADP-ribosylation or PARylation increases more than 500-fold in the presence of DNA-strand breaks. 8 Although PARP1 accounts for the vast majority (B85%) of PAR polymer synthesis, five other members have catalytic activity of PARylation, namely PARP2, PARP3, PARP4 and PARP5A/B (also known as tankyrase1/2). 9 Recently, Hottiger reported a new classification for the ADP-ribosyl transferases grouping the PARP family members and distinguishing proteins with mono or poly(ADP)ribosylation activity. 9 Here, we provide an overview on the roles of PARP1, focusing on its involvement in cellular stress management, and the possibility to target PARP1 for the treatment of cancer. We will devote special attention to the discovery of predictive biomarkers that may improve patient selection.
PARP1 IN PHYSIOLOGICAL AND PATHOLOGICAL RESPONSES
PARP1 is historically known as a sensor of DNA nicks, contributing to the single-strand break repair, the orchestration of the DNA damage response (DDR) and the maintenance of genomic stability. 10, 11 Nevertheless, several recent studies have led to the identification of a plethora of novel roles for PARP1, placing its activity at the center of the cellular stress response network. PARP1 À / À knockout mice exhibit (i) increased genetic instability as measured by the frequency of micronuclei, sister chromatid exchanges and other chromosome aberrations as well as (ii) major DNA repair defects coupled to hypersensitivity to alkylating agents and g-radiation.
12 Nonetheless, the inhibition of PARP is not lethal for mammals, 13 and Parp1 À / À mice are viable and fertile, even though they manifest accelerated aging and exhibit a higher incidence of spontaneous or carcinogen-induced tumors than wild-type controls.
14 However, the simultaneous loss of PARP1 and PARP2 is lethal at the onset of gastrulation, suggesting that the two PARP proteins have redundant roles in embryogenesis. 15 PARP1 and the DDR Due to the continuous exposure to endogenous and exogenous DNA-damaging insults, cells experience DNA lesions such as SSBs and double-strand breaks (DSBs) that require continuous activation of DNA repair pathways (Box 1).
The levels of PARP1 protein increase in response to DNA damage, 16 and PARP1 contributes to both SSB and DSB repair. PARP1 associates with persisting SSBs or DSBs where it becomes activated and catalyzes the PARylation of multiple nuclear acceptor proteins adjacent to the DNA break including that of PARP1 itself, histones, DNA repair proteins, chromatin regulators and transcription factors. 7, 17 PARylation facilitates the chromatin decondensation, 1 thereby rendering DNA lesions accessible to the repair machinery. In addition, PARP1 may favor the assembly of protein complexes involved in DDR. 18, 19 Although controversial, 20, 21 PARP1 may operate in base excision repair (BER) by detecting the presence of SSBs, as well as by recruiting and modulating the activity of repair proteins such as X-ray cross-complementing gene 1 (XRCC1), DNA ligase III and 8-oxoguanine-DNA glycosylase. 11, 22 PARP1 may contribute to nucleotide excision repair, as suggested by the finding that ultraviolet radiation-induced direct DNA lesions including thymine dimers-which are removed by the nucleotide excision repair machinery-activate PARP1. 23 PARP1 operates in nucleotide excision repair by stabilizing damaged DNA-binding protein 2 24, 25 or by associating with Xeroderma Pigmentosum Complementation Group A. 26 PARP1 is believed to promote the repair and restart of stalled replication forks during homologous recombinational repair (HRR) by attracting MRE11, a component of the MRN (Mre11-Rad50-Nbs1) complex, to collapsed replication forks. 27 The combined action of PARP1 and BRCA2 may also protect stalled replication forks from Mre11-mediated degradation. 28, 29 Moreover, PARP1 activates HRR by antagonizing the suppressive impact of the KU70-KU80 heterodimer and/or ligase IV-two key players of non-homologous end joining (NHEJ)-on HRR. [30] [31] [32] PARP1 is essential to accomplish alternative (A) NHEJ. 33, 34 Moreover, PARP1 may cooperate with DNA-PKcs in the initiating step of canonical (C) NHEJ. 35 However, the precise contribution of Abbreviations: AIF, apoptosis-inducing factor; AMPK, AMP kinase; ATM, ataxia-telangiectasia mutated; BER, base excision repair; DDB2, damaged DNA-binding protein; DNA-PKc, DNA-dependant protein kinase; HRR, homologous recombinational repair; NAD þ , nicotinamide adenine dinucleotide; NER, nucleotide excision repair; NHEJ, non-homologous end joining; PARP, poly-(ADP-ribose) polymerase; ROS, reactive oxygen species; TNF-a, tumor necrosis factor a; XPA, xeroderma pigmentosum complementary group A; XRCC1, X-ray repair cross-complementing 1.
Box 1 DNA repair pathways
Base excision repair (BER) is a DNA repair pathway that removes non-bulky base lesions in form of the free bases, as they occur after spontaneous, oxidative and alkylating DNA damage. 181 BER includes different effectors acting at distinct steps. In human cells DNA glycosylases (for example, 8-oxoguanine-DNA glycosylase (OGG1), alkyl-N-purine-DNA glycosylase (ANPG), endonuclease III DNA glycosylase hNTH1) retrieve the damaged bases [182] [183] [184] [185] generating abasic sites that then are cleaved by AP endonuclease 1, APE1, inducing singlestrand breaks (SSBs). 186 PARP1 and PARP2 attract different repair enzymes to the DNA lesion site (for example, X-ray cross-complementing factor 1 XRCC1, polymerase b, proliferating cell nuclear antigen (PCNA), ligase 3). 37 Nucleotide excision repair (NER) is a pluripotent pathway for recognition and removal of bulky helix disturbing DNA lesions generated by UV irradiation and anticancer agents such as cisplatin (CDDP). NER involves dual incisions that bracket lesion site and release of the 24-32 nucleotide-long oligomer containing damaged residues. Two sub-pathways are identified, (i) the transcription-coupled repair (TC-NER) in transcriptionally active genes and (ii) the global genomic repair (GG-NER) operating on the entire genome. 187 RNA polymerase II is stalled at the DNA lesions are sensed by cockayne syndrome WD repeat proteins (CSA and CSB) in TC-NER and by Xeroderma pigmentosum (XPC) in GG-NER. 188 In both pathways, the lesions are excised by endonucleases (for example, XPG and ERCC1-XPF) and resulting DNA gap is then filled and sealed by DNA polymerases d, e and ligase III, respectively. NER also contributes to repair intra and interstrand crosslinks (ICL) and oxidative DNA damage. Mismatch repair (MMR) is a system that recognizes and repairs DNA replication and recombination errors, such as mismatched bases, deletions and insertions. In human cells two major heterodimers: Msh2/Msh6 (MutSa), and Msh2/ Msh3 (MutSb) recognize DNA mismatches and trigger their removal by recruiting MutLa (MLH1/PMS2) and MutLb (MLH1/PMS1) complexes. Direct repair (DR) is the direct reversal of a damaged base to its native state without excision and de novo DNA synthesis. At present, there are three types of DNA damage known to be repaired by chemical reversion including: photoreactivation process by photolyases, O-methylation (in O 6 -Guanine, O 4 -Thymine and phosphates) is directly reversed by the protein O 6 -methylguanine DNA methyltransferase (MGMT) and oxidative demethylation of N-methyl groups by AlkB family proteins. MGMT transfers the methyl/alkyl groups from mutagenic DNA base lesions O 6 -meG and O 4 -meT generated by chemotherapeutic agents like dacarbazine and TMZ onto one of its nucleophilic cysteine residues situated in the protein active site. Importantly, the cysteine acceptor site is not regenerated after the transfer, and therefore these proteins are not true enzymes. The self-methylated DNAmethyltransferases are referred to as suicidal DNA repair proteins, as they are irreversibly inactivated during this stoichiometric repair reaction. 73, 189 Homologous recombination (HR) is a prominent DNA homology-directed double-strand break (DSB) repair pathway that in general proceeds in error-free manner. In HR repair pathway, Rad51 protein catalyzes DNA-strand exchange between similar or identical DNA molecules. DSB is repaired using the homologous non-damaged sister chromatid or homologous chromosome as a template. In human cells, HR requires BRCA1 and BRCA2, RAD51 and FANC proteins. HR only acts during the S and G2 phases of the cell cycle.
PARP1 to C-NHEJ-at least in human cells-remains to be established 24 , and a role of PARP3, rather than PARP1, in promoting the DSB repair during C-NHEJ has recently been proposed. 36 Given its multiple roles in DDR, pharmacological inhibitors of the enzymatic activity of PARP are considered as promising agents for anticancer therapy (see below). PARP inhibitors subvert SSB repair, thereby inducing the formation of stalled replication forks and/or suppress DSB repair. Alternatively, PARP inhibitors may act by trapping PARP1 at the SSB intermediate formed during BER, thus impairing the access of BER proteins to the DNA lesion and provoking the obstruction of replicative forks. 37 PARP inhibitors are particularly effective against BRCA1-and BRCA2-defective tumors by provoking synthetic lethality. 16 In this context, a current model suggests that, in conditions of HRR deficiency (HRD), which may result from loss-of-function mutations in BRCA1/2, DNA damage sensors (NBS1, ataxia-telangiectasia mutated (ATM), ATR, CHK1 and CHK2) or RAD51, the inhibition of PARP would trigger the error-prone NHEJ mechanism, resulting in genetic instability and/or cell death. 38 Consistent with this hypothesis, HRR-deficient cells become insensitive to PARP inhibitors when NHEJ is disabled by DNA-PKcs inhibitors.
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PARP1 as a modulator of cell survival and death PARP1 is believed to have key functions in the modulation of the cellular response to several stressors. 19 Upon exposure to DNAdamaging agents or endogenous oxidative stress, PARP1 becomes active and generates signals that either favor adaptation to stress or stimulate cell death. The cell's ultimate fate depends on the nature of the stimulus, the severity of the damage, the cellular context and the balance between the activation versus inhibition of PARP.
Uncontrolled PARP1 activation may result in the induction of cell death. Upon extensive DNA damage that saturates the DNA repair machinery, prolonged PARP activation can result in the depletion of NAD þ and subsequently of ATP pools, thus inducing necrotic cell death. [39] [40] [41] Moreover, PARP1 may act downstream of the kinases RIPK1 and RIPK3 in TRAIL-induced necroptosis. 42 As compared with wild-type controls, Parp1 À / À mice are more resistant to several paradigms of injury-induced tissue degeneration, reinforcing the notion that PARP1 contributes to the execution of regulated necrosis. 43 Although the cleavage and inactivation of PARP1 by caspases is a well-recognized byproduct of apoptosis, 5 the implication of PARP1 in cell death is controversial and limited (for more details see Virag et al. 44 ). Nevertheless, PARP overactivation seems to trigger a peculiar form of cell death called 'parthanatos' that is dependent from apoptosis-inducing factor but independent from caspases. According to one proposed model, the activation of PARP1 and the translocation of PAR polymers from the nucleus to the mitochondria would lead to the mitochondrial release of apoptosis-inducing factor, which then translocates to the nucleus and participates in chromatin degradation. 45, 46 The binding of apoptosis-inducing factor to PAR may be important for the activation of parthanatos. 47 In striking contrast with its role in the execution of cell death, PARP1 also has a pivotal function in cell survival processes. Indeed, PARP1 activity is required for the maintenance of genomic stability, and PARylation is implicated in both DNA repair (see above) and mitosis. 48 Moreover, growing evidence suggests that PARP1 activation might be involved in the decision of cells to induce a cytoprotective autophagic response, thereby avoiding cell death. [49] [50] [51] Reportedly, PARP1 may mediate autophagy induction through the activation of AMP kinase. [52] [53] [54] Beyond its inhibitory action on the DDR, PARP inactivation may be cytotoxic for additional reasons. Thus, PARP inhibition may (i) elicit a cell cycle arrest in the G 2 /M phase; 16 (ii) increase the level of genomic instability, including a hyperrecombinant phenotype, 55 telomere shortening 56, 57 and chromosome aberrations (for example, chromosome fusion, sister chromatid exchange, micronuclei and aneu-/tetraploidization); 13, 58 and (iii) activate the intrinsic pathway of apoptosis, as recently demonstrated by our group on a panel of CDDP-resistant NSCLC cell lines. 59 Other functions of PARP1 Apart from its contribution in recovering from DNA damage and in regulating cell death, PARP has an important role in inflammatory processes and in ischemia-reperfusion injury. 60, 61 PARP1 acts during acute and chronic inflammation by (i) stimulating the secretion of pro-inflammatory mediators (for example, TNFa, NF-kB and HMGB1), (ii) regulating the differentiation of T cells and (iii) controlling the maturation of B lymphocytes. 62 In line with these observations, some preclinical studies demonstrated that the inhibition of PARP has antidiabetic effects and confers cardioprotection and neuroprotection in vascular diseases. [63] [64] [65] Both PARP1 and PARP2 have been implicated in the regulation of bioenergetic metabolism. 66 Through yet ill-defined mechanisms, PARP1 hyperactivation may also contribute to the pathogenesis of Alzheimer's disease. 67, 68 Finally, PARP activation downregulates mitochondrial respiration and oxidative metabolism, thereby enhancing age-related diseases (for example, diabetes and obesity). This effect could be ascribed to three different mechanisms, namely (i) direct PARylation of some metabolic enzymes potentially affecting their catalytic activity, (ii) effects on metabolism-relevant transcription factors and (iii) alteration of cellular NAD þ concentrations. 66 In this context, PARP1 inhibitors have been evaluated as agents that may avoid excessive necrosis after cardiac or brain ischemia.
PARP INHIBITORS-PRECLINICAL DATA
Several distinct PARP inhibitors may synergize with conventional DNA-damaging agents, such as ionizing radiation and chemotherapeutics, in increasing their in vitro and in vivo effectiveness against tumor cells. This applies to investigational agents such as 3-aminobenzamide, NU1025 (8-hydroxy-2-methylquinazolin-4-(3H)one), NU1085 (2-(4-hydroxyphenyl)benzamidazole-4-carboxamide), PJ34 (phenanthridinone), as well as to recently developed PARP inhibitors including ABT888 (also known as Veliparib), AG014699 (also known as Rucaparib, AG14447 or PF-01367338), CEP8983 (a 4-methoxy-carbazole derivate), E7016, GPI 15427 and olaparib (also known as AZD2281 or KU-0059436).
Inhibition of PARP1 by olaparib or similar agents increases the radiosensitivity of glioblastoma 69, 70 and non-small-cell lung carcinoma, 71 both in vitro and in vivo. The underlying mechanism of olaparib-mediated radiosensitization was found to involve DNA replication-generating DSBs. 70 Translesion synthesis (TLS) is a DNA damage tolerance pathway that allows the DNA replication machinery to replicate past DNA lesions by switching on the specialized translesion DNA polymerases (for example, Y-family polymerase H and A-family polymerase Q), which is often overactivated in cancer cells. TLS operates if the S-phase has been initiated in spite of DNA damage. Non-homologous end joining (NHEJ) is a pathway that repairs double-strand breaks generated by closel-spaced nicks on the complementary strands. In NHEJ DSB is ligated without need for a homologous template this process involves KU70 (also known as XRCC6), KU80 (also known as XRCC5), DNA-dependant protein kinase catalytic subunit (DNA-PKcs), artemis, ligase 4 and XRCC4-XPF. NHEJ is cell cycle independent and rapid though highly error-prone.
Temozolomide (TMZ) is an alkylating agent currently used for the treatment of malignant glioma and metastatic melanoma that leads to the formation of a wide spectrum of methyl DNA adducts, including O-methyl adducts, which are repaired by the DR pathway, 72 and N-methyl adducts, which are removed by DNA glycosylase-initiated BER and by the AlkB family of oxidative DNA demethylases during DR. 73 To date, TMZ resistance is believed to arise from two distinct mechanisms, namely (i) the increased activity of the O 6 -methylguanine DNA methyltransferase that eliminates the O-methyl adducts or (ii) a deficiency in MMR, which results in microsatellite instability, and, consequently, in the lack of repair of-and increased tolerance to-O-methyl adducts. 74, 75 Inhibition of PARP with consequent defective BER enhances the cytotoxicity of TMZ, correlating with an increase in TMZ-induced N-methyl adducts. 76 Such synergistic effects were observed in different cell types responding to TMZ, namely (i) in melanoma and cervical carcinoma cells, if combined with the pharmacological PARP inhibitor GPI 15427 or small interfering RNAs for the depletion of PARP1 and PARP2, (ii) in neuroblastoma cells, if combined with AG014699, both in vitro and in vivo, in xenografted tumor models, 77, 78 and (iii) in a other tumor types, including those a priori non-responsive to TMZ, if combined with ABT888. 79 Remarkably, in leukemia cells, the combination between ABT888 and TMZ inhibited the growth of MMR-deficient and MMRproficient cells regardless of the O 6 -methylguanine DNA methyltransferase level. 80 Intriguingly enough, GPI 15427 enhanced the in vivo antitumor effects of TMZ even against PARP1-depleted cells. 78 This finding indicates that GPI 1542 might act on other PARP isoforms than PARP1 or might have yet-to-be-elucidated off-target effects.
The association of PARP inhibitors with cisplatin (CDDP) showed additive or hyperadditive effects on cervical cancer, liver cancer and testicular germ cell tumor cell lines. [81] [82] [83] Moreover, when added to NSCLC cells, CDDP synergizes with PJ34, CEP8983 or PARP1-depleting small interfering RNAs with regard to the inhibition of cell proliferation, induction of DNA damage foci and activation of the intrinsic apoptotic pathway.
84 BRCA1-/2-mutated breast cancer xenografts were also more sensitive to the combination of AG014699 and carboplatin (which is chemically related to CDDP) than to each drug alone. 85 Topoisomerases I and II have pivotal roles in DNA replication and transcription, in thus far that they 'unwind' the double DNA helix. 86 Topoisomerase inhibitors act by stabilizing this unwinded form of the DNA helix, thus causing the subsequent conversion of transient SSBs into permanent DSBs during DNA replication.
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PARP1 interferes with the DNA relaxation activity of topoisomerase I either through direct protein-protein interaction or through PARylation. 88 Importantly, PARP inactivation potentiates the cytotoxicity of topoisomerase I inhibitors (for example, camptothecin and topotecan) on neuroblastoma, colorectal lung, breast and ovary human cancer cells, 77, 89, 90 as well as that of topoisomerase II inhibitors (for example doxorubicin, C-1305) on liver, ovarian and BRCA1-positive breast cancer cells. [91] [92] [93] Targeting DNA repair deficiencies PARP inhibitors given as standalone therapies have been shown to mediate some degree of cytotoxicity against human cancer cell lines grown in vitro, 16 as well as in a few in vivo human and murine tumor models. 85 PARP inhibitors are particularly toxic when they are administered to BRCA-deficient cells, suggesting that PARP inhibition and HR defects might be synthetically lethal for cancer cells. 94 Thus, pharmacological or genetic inactivation of either PARP1, BRCA1 or BRCA2 alone is compatible with cell survival, whereas their simultaneous inhibition is not. 16 This discovery raised the possibility to exploit PARP inhibitors for the treatment of breast or ovarian cancers with defects in BRCA1 or BRCA2. 95 Of note, HR-deficient cells susceptible to PARP inhibitors present constitutive PARP hyperactivation 96 leading to an increase in the intracellular PAR levels without any consistent increase in the level of PARP protein expression. 97 As a result, increased levels of PAR may predict responsiveness to PARP inhibitors.
Apart from BRCA mutations, constitutive modifications of the expression of other DDR effectors may induce HRD, a condition that has been referred to 'BRCAness' and that may be efficiently targeted by PARP inhibitors (Box 2). In this context, Aurora A overexpression and MRE11 downregulation may be explored as surrogate markers of BRCAness. Aurora A is a mitotic kinase with essential roles in cell cycle control and mitosis. 98, 99 Aurora A is overexpressed in multiple cancers, and this deregulation has been causally linked to tumorigenesis. 100 The overexpression of Aurora A may affect DSB repair by preventing the recruitment of RAD51 to DNA DSBs by a mechanism that would require the inhibition of the checkpoint kinase CHK1. 101 As a result, DSB repair by HR is impaired and cells become susceptible to PARP inhibitors. Aurora A overexpression is a candidate predictive biomarker of PARP inhibitor sensitivity.
The phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that inhibits the oncogenic phosphoinositide 3-kinase (PI3K)-AKT-mTOR pathway downstream of epidermal growth factor receptor (EGFR) signaling. Loss of PTEN is most
Box 2 BRCAness
Germline-transmitted inactivating mutations of the BRCA1 or BRCA2 genes compromise. HR proficiency, predispose to female breast (85% lifetime risk), ovarian (10-40%), male breast, pancreatic and prostate cancer. 192 Sporadic tumors may display 'BRCAness', that is, HR defects without mutations in BRCA1 or BRCA2. 171, 193 BRCAness can be explained by epigenetic inactivation (for instance due to promoter methylation) of BRCA1 or BRCA2, (epi)mutations in other genes, post-translational protein modifications, as well as pharmaclogical inhibitors that inactivate HR-dependent repair:
Sporadic ovarian (5-31%) (55% of high-grade serous ovarian carcinoma) and breast cancers (11-14%) (in particular TNBC) present an epigenetic silencing of BRCA1 by methylation of it's promoter. 171, 194 ATM and MRE11 195 mutations in lymphocytic leukemia cause defects in the early steps of the HR pathway. Aurora A, a mitotic kinase, overexpressed in a diverse array of cancers may inhibit the recruitment of RAD51 at the DNA damage site. 101 Fanconi gene promoter methylation has been reported in lung, cervical and ovarian cancer. [196] [197] [198] The amplification of EMSY a protein capable of silencing BRCA2 is observed in sporadic breast (13%) and high-grade ovarian cancer (17%). 172 ETS transcription factors are aberrantly expressed in different cancers and may repress BRCA1/2 and subsequently impair HRR.
140
PARP1 binding protein PARPBP (also known as PARI or CI2orf48) may inhibit HR by interacting with RAD51 at replication forks. 177 PARPBP is overexpressed in pancreatic ductal carcinoma and positively regulate the poly(ADP-ribosyl) ation activity of PARP1. 175, 176 Pharmacological inhibitors of the HR are being developed for cancer therapy. In particular, specific inhibitors of ataxiatelangiectasia mutated (ATM) kinase, cyclin-dependent kinase 1 (CDK1), epidermal growth factor receptor (EGFR), heat-shock protein of 90 KDa (HSP90), histone deacetylases (HDAC), phosphoinositide 3-kinase (PI3K) pathway and BCR-ABL (imatinib) may compromise HR (see main text).
frequently found in glioblastoma, NSCLC, as well as endometrial (up to 80% of cases), breast and prostate cancers. 102 The impact of PTEN loss on DSBs repair is controversial. [103] [104] [105] Some authors reported that the absence of PTEN sensitized cancer cells to the inhibition of PARP, presumably by downregulating RAD51 and consequently impairing HR. 106, 107 Accordingly, KU0058948 selectively killed endometrioid endometrial cancer cells displaying PTEN loss and HR deficiency. 108 Nevertheless, a recent study performed on primary prostate cancers has weakened this conclusion, as the authors failed to observe a significant correlation between, on one hand, the PTEN status and, on the other hand: (i) RAD51 expression levels, (ii) sensitivity to PARP inhibitors and (iii) the expression of genes associated to synthetic lethality, such as RAD51, ATM, PRKDC, BRCA1, BRCA2, MRE11, CDK6 and MSH2. 105 Instead, PARP I sensitivity was associated with a defect in MRE11 expression coupled to PARP hyperactivation.
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MRE11 is a key component of the MRN complex (Mre11-Rad50-Nbs1) that promotes the restart of stalled replication forks and induces HRR by recruiting and activating the ATM kinase. 27, 109, 110 Thus, MRE11 deficiency may be a more accurate predictive marker for PARP inhibition sensitivity than PTEN deficiency.
PARP inhibitors can kill cells lacking DDR pathways other than HRR. Thus, HRR-proficient human mesothelioma, NSCL, epithelial ovarian and cervix cancer cell lines that had acquired CDDP resistance due to prolonged culture in the presence of the drug, upregulated the activity of PARP (and hence promoted PARylation of cellular, mostly nuclear proteins). 59 When exposed to PARP inhibitors, these cells increased the number of BRCA1 and RAD51 foci, which are both surrogate markers of HRR activation. 111 Although these cells were proficient in the initiation of BER, they were deficient in XRCC1 and polymerase b. 59 Intriguingly, synthetic lethality has been observed for Chinese hamster ovarian cells and human ovarian, breast and cervix cancer cells when they were first XRCC1-depleted and then treated with either PARP or DSB inhibitors (for example, ATM and DNA PKC inhibitors). 21, 112 These results suggest that the absence of XRCC1 expression may constitute a biomarker that predicts sensitivity to PARP inhibitors.
Manipulating HRR for sensitization to PARP inhibitors One approach to extend the indications of PARP inhibitors to HRRproficient cancers might consist in combining them with chemical inhibitors of HRR. Prospective targets related to the HRR pathway include ATM, the cyclin-dependent kinase 1 (CDK1), EGFR, heatshock protein of 90 KDa, histone deacetylase and the PI3K pathway (see below). Moreover, gimeracil has been discovered as a drug that inhibits the early steps of HRR. 113 The combined inhibition of PARP1 and ATM is incompatible with embryogenesis, as revealed by the phenotype of double knockout mice. 114 ATM, a kinase triggered by DNA damage (that is, DSB), induces DDR (that is, HRR and NHEJ) and cell cycle checkpoint activation that is often dysregulated in cancer. 115 PARP inhibitors are extremely efficient against cancer cells bearing ATM defects, as shown in the context of Mantle cell lymphoma. [116] [117] [118] PARP-inhibited cells were also found to be sensitive to the inhibition of the DNA-PK variant involved in NHEJ. 32, 119, 120 Notable differences exist between different proteins involved in NHEJ. This applies to DNA-PK and KU80 in the sense that Parp1
DNA-PK
À / À mice are viable, while Parp1 À / À KU80 À / À mice are not. 121 Of note, the association of DNA-PK and ATM inhibitors was unable to kill PARP1-deficient cells more efficiently than ATM inhibitors alone. 121 The synergistic effect of PARP inhibitors and ATM inhibitors is encouraging and warrants further investigation.
Another downstream target of DNA-PK is the non-receptor protein kinase c-ABL that phosphorylates RAD51. 122, 123 c-ABL is specifically targeted by imatinib mesylate, a tyrosine kinase inhibitor that transformed the prognosis of patients with gastrointestinal stromal tumors and chronic myeloid leukemia. 124, 125 Imatinib downregulates the HRR and renders human prostate and pancreatic cancer cell lines susceptible to radiotherapy and chemotherapy (that is, gemcitabine and mitomycine C). 126 As a result, it may be worthwhile to explore the association of imatinib with PARP inhibition.
Some recent results indicate that BRCA1 is functional only upon phosphorylation by CDK1, a core component of the cell cycle machinery. 127 The depletion of CDK1 by means of a doxycycline inducible shRNA compromises the ability of H1299 NSCLC cells to form RAD51 foci in response to g-irradiation.
128 Accordingly, the simultaneous inhibition of CDK1 and PARP synergistically inhibited the growth of human NSCLC xenografts and of transgene-induced lung adenocarcinomas. 128 EGFR inhibitors, namely tyrosine kinase inhibitors (that is, erlotinib and gefitinib), and monoclonal antibodies (for example, cetuximab) are effective treatments in EGFR mutated NSCLC and KRAS wild-type colorectal cancers respectively. 129, 130 Intriguingly, EGFR inhibitors attenuate the repair of DSBs by HR (that is, by downregulation of BRCA1) and NHEJ (that is, by inhibiting the phosphorylation and translocation of DNA-PK to the nucleus), 131, 132 conferring susceptibility to PARP inhibition. It will be interesting to learn whether these preclinical results can be confirmed in vivo, in suitable xenograft models.
Inhibitors of the chaperone heat-shock protein 90 such as allylamino-17-demethoxygeldanamycin 17-AAG-a compound that is currently under clinical investigation 133, 134 -may inhibit HR by provoking the degradation of some proteins such as BRCA2 and RAD51. 135 Consistent with this notion, 17-AAG exacerbates the cytotoxic effects of both irradiation and olaparib on glioblastoma multiforme. 136 Along similar lines, histone deacetylase inhibitors can affect the DDR by modifying the expression of proteins involved in HR. 137 Indeed, the histone deacetylase inhibitor suberoylanilide hydroxamic acid efficiently inhibits the growth of hepatocellular carcinoma cells when associated with olaparib. 138 These findings are encouraging, but need further confirmation.
ETS gene fusions are found in a wide array of cancers, including Ewing's sarcoma, acute myeloid leukemia and prostate cancer. 139 PARP inhibition suppresses the growth of ETS gene fusion-positive but not ETS gene fusion-negative xenografts, along with the accumulation of double-strand DNA lesions. 140 ETS was recently identified as the transcription factor with the highest number of BRCA1/2 binding motifs. 141 ETS may repress the BRCA promoter upon its activation by the mitogen-activated protein kinase pathway. 142, 143 PI3K inhibitors have been reported to stimulate ERK-dependent ETS1 activity and subsequent HR impairment due to decreased expression of BRCA1/2 and concomitant upregulation of PAR levels indicative of increased PARP activity. 141, 144 As a result, triple-negative breast cancer (TNBC) BRCA-proficient cells succumbed to the combined pharmacological inhibition of PI3K and PARP. 141 These results indicate that the presence of ETS gene fusions predict sensitivity to PARP inhibitors. Furthermore, they suggest that therapeutic measures that upregulate ETS1 function may synergize with PARP inhibitors.
HER2 as a modulator of the response to PARP inhibitors HER2 overexpressing (HER2 þ ) human breast cancer cell lines are susceptible to PARP inhibition by ABT888 and AZD2281 regardless of their HR status. HER2 knockdown abrogated their PARP hypersensitivity. 145 Of note, one third of human breast cancers are HER2 þ , and the overexpression of HER is a negative prognostic factor. 146 HER2 overexpression has been linked to the activation of NF-kB. 147 Given the fact that PARP is a coactivator of NF-kB, 148 it is well possible that the susceptibility of HER2 þ breast cancer cells to PARP inhibition can be explained by their dependence on the NF-kB signaling pathway. 145 As a result, HER2 overexpression might predict the response of breast cancer cells to PARP inhibition. 53BP1 and acquired PARP resistance Upon long-term exposure to PARP inhibitors, BRCA-deficient tumors develop an acquired resistance to these compounds through a mechanism that often implies the restoration of HR proficiency. 149 Thus, pancreatic cancer cells carrying a BRCA2 mutation became resistant to PARP inhibition due to intragenic deletions restoring the open-reading frame of BRCA2. 150, 151 Along similar lines, loss of 53BP1 (a DNA damage-responsive intranuclear protein involved in HR and NHEJ), an event that restores HR, can render BRCA1-deficient cells resistant to PARP inhibitors 152 and other DNA-damaging agents such as CDDP. 153 Thus, 53BP1 expression levels (or functionality) may constitute an interesting biomarker to identify HR-deficient tumors that would respond to PARP inhibitors.
CLINICAL EVALUATION OF PARP INHIBITORS
Current clinical trials involve multiple PARP inhibitors, such as AZD2461 and olaparib (also known as AZD2281 or KU-0059436) from AstraZeneca (Cambridge, UK), veliparib (also known as ABT888) from Abbott (Green Oaks, IL, USA), CEP9722 from Cephalon (Frazer, PA, USA), rucaparib (also known as AG014699, AG14447 or PF-01367338) from Clovis Oncology Inc. (Boulder, CO, USA) Pfizer, GPI-21016 from Eisai/MGI Pharma (Tokyo, Japan), MK-4827 from Merck (Whitehouse Station, NJ, USA), INO-1001 from Inotek/Genentech (San Francisco, CA, USA), BMN-673 from BioMarin Pharmaceutical Inc. (Novato, CA, USA) and E7449 from Eisai Inc., (Woodcliff Lake, NJ, USA) (http://www.clinicaltrials.gov/). All these compounds are administered orally. We will not discuss the highly deceptive clinical evaluation of iniparib (also known as BSI-201 or SAR240550) from BiPar/Sanofi-Aventis (Paris, France) that was erroneously considered as a PARP inhibitor, yet lacks any specific activity at this level. 154 PARP inhibitors are being evaluated in oncology either as monotherapeutic agents or in combination with other anticancer therapies, seeking higher efficiency (Figure 1 ). In only one quarter of clinical trials, patients were selected based on the presence of confirmed or clinically suspected HRR deficiencies (BRCA mutations, basal-like or TNBC, high-grade EOC with platinum sensitivity), and rather few studies included biomarker analyses (Tables 2-3) .
The pharmacokinetic and pharmacodynamic characteristics of olaparib have first been evaluated in a phase I trial on 60 patients with solid tumors (including ovarian, breast and prostate cancer), 22 of whom carried BRCA1 or BRCA2 mutations. 95 Importantly, objective tumor responses were observed only among BRCA carriers with 63% clinical benefit rate. Encouraged by these results, a supplemental cohort of 50 ovarian patients bearing BRCA1 or BRCA2 mutations was included. Among them, 13 were platinumrefractory (progressive disease, PD, during previous platinumbased chemotherapy), 24 were platinum-resistant (PD o6 months after previous platinum-based chemotherapy) and 13 were platinum sensitive (PD 46 months after previous platinumbased chemotherapy). These patients exhibited a response rate (according to RECIST criteria or reduction in the circulating levels of the ovarian cancer-associated marker CA-125) of 23%, 45% and 69%, respectively. 155 The effectiveness of olaparib correlated with BRCA mutation and platinum sensitivity.
The aim of a subsequent phase II trial was to determine the efficacy of olaparib in BRCA1 or BRCA2 mutation carriers with advanced refractory breast cancer (54 patients) or epithelial ovarian cancer (EOC, 57 patients). For two cohorts receiving 400 or 100 mg olaparib per day, the ORR was 41% and 21% (clinical benefit rate 52% and 26%) in breast cancer and the ORR was 33% and 13% (clinical benefit rate 66% and 42%) in EOC, respectively. 156, 157 In a recent non randomized phase II study, women with advanced recurrent high-grade serous or undifferentiated ovarian carcinoma or TNBC (63 patients) were stratified according to the presence of BRCA1 or BRCA2 mutations and treated with olaparib 400 mg twice daily. ORR was 41% for BRCA-mutated patients and surprisingly high-24%-for nonmutated patients. 158 Thus, a fraction of ovarian and breast cancers that lack BRCA mutations can respond to PARP inhibitors.
A randomized study has compared Olaparib monotherapy (200 or 400 mg bid) with pegylated liposomal doxorubicin (50 mg/m 2 ) both given for 28 days, in heavily pretreated EOC with confirmed BRCA1/2 mutation and a platinum-free interval shorter than 12 months (reflecting platinum resistance or intermediate responses). The ORR of 31% for the group receiving 400 mg olaparib was consistent with previous studies. 155, 156 However, the trial failed to reveal significant differences in progression-free survival (PFS) or ORR between the groups, 159 with the particularity that PFS for pegylated liposomal doxorubicin was rather high compared with prior studies in EOC. 160 There are indications that BRCA1/2-mutated tumors are more anthracycline-sensitive than non-mutated tumors, 111 and this might explain the high efficacy of pegylated liposomal doxorubicin in this study, which only enrolled BRCA1/2-mutated patients. However, the patients in this study were poor responders to CDDP and hence belonged to a subgroup of patients that reportedly exhibit low responses to PARP inhibitors. 155 PARP inhibitors have been evaluated in NSCLC (Oza, ASCO 2012, abstract 5001) and EOC as a maintenance therapy after platinum treatment. 161 PFS was significantly longer in patients with platinum-sensitive high-grade serous EOC treated with 400 mg bid olaparib compared to placebo after two or more platinumbased regimens (median, 8.4 months vs 4.8 months; HzR, 0.35; 95% CI, 0.25-0.49; Po0.001). The study groups were well balanced with 22% of BRCA mutations, and subgroup analyses led to the conclusion that all patient groups profited from olaparib independently from the BRCA mutational status, age, ethnic origin or the baseline response to platinum. However, an interim analysis of OS revealed no significant improvement (HzR, 0.94; 95% CI, 0.63-1.39; P ¼ 0.75). The preplanned subgroup analysis revealed the greatest clinical benefit in (germline or somatic) BRCA-mutated patients (median: 11.2 vs 4.3 m; HzR, 0.19; 95% CI: 0.11-0.32; Po0.0001) (Ledermann, ASCO 2013, abstract 5505). 161 One of the major challenges of regimens combining olaparib with conventional chemotherapeutics is myelotoxicity. 162 However, the association of olaparib with metronomic cyclophosphamide or TMZ is rather well tolerated, allowing full-dose administration of chemotherapy. 163, 164 In chemonaïve metastatic melanoma, the combination therapy with TMZ seems of real interest. In a phase I trial, one patient benefited from a complete response that has been lasting for 45 years post therapy. 164 A phase II trail yielded encouraging results with a response rate of 17.4% and stable disease in 36% of the patients 6 months post therapy. 165 Several studies have associated olaparib with targeted therapies. Ongoing phase I studies are combining PARP inhibition with (i) the PI3K inhibitor BKM120 in recurrent TNBC and high-grade EOC (NCT01623349), (ii) the VEGFR inhibitor cediranib in ovarian and breast cancer (NCT01116648), (iii) bevacizumab plus carboplatin and paclitaxel in EOC (NCT00989651), (iv) the CDK inhibitor dinaciclib plus carboplatin in advanced solid tumors (NCT01434316) or (v) the anti-CD20 monoclonal antibody rituximab plus bendamustine in hematological malignancies (NCT01326702) (www.clinicaltrials.gov). The results of these studies are still elusive.
In synthesis, PARP inhibitors have been yielding promising clinical results in several trials. When administered alone, PARP inhibitors are well tolerated and efficient provided that they are used against DNA repair deficient tumors. The subgroup of patients targeted by most ongoing clinical trials of PARP inhibitors Abbreviations: bid, twice a day; CBR, clinical benefit rate; CI, confidence interval; CV, cerebrovascular accident; EOC, epithelial ovarian cancer; EP, endpoint; GI, gastro-intestinal; HR, hazard ratio; MDS, myelodysplastic syndrome; OS, overall survival; OR, objective response rate; ORR, overall response rate; PARP, poly(ADP-ribose) polymerase; PD, pharmacodynamics; PFS, progression-free survival; PFI, platinum-free interval; RR, response rate; TNBC, triple-negative breast cancer.
Anticancer profile of PARP inhibitors J Michels et al carries BRCA mutations and platinum-sensitive tumors, because this subgroup showed the most promising results in early clinical development. 155 Although BRCA mutations render cells sensitive to platinum and PARP inhibition, 166 there is no absolute correlation between the BRCA mutational status, platinum sensitivity and clinical responses. Thus, a significant fraction of patients with BRCA non-mutated EOC demonstrated a prolonged PFS with olaparib. 161 Moreover, a significant fraction of BRCAmutated platinum-resistant EOC remained sensitive to PARP inhibitors. 155 Clinical features considered as surrogate biomarkers of HRD such as unfavorable pathobiological parameters (TNBC, high-grade serous EOC) and platinum responsiveness in a BRCA-mutated context may not be sufficiently specific in the prediction for the response to PARP I.
For instance, as reported by the Cancer Genome Atlas, only 50% of high-grade EOCs are HRR deficient. 167 Moreover, only 20% of TNBC may be BRCA mutated. 168 These findings underscore the need for suitable biomarkers that diagnose DNA repair defects and predict responses to PARP inhibitors.
CONCLUDING REMARKS: BIOMARKER DISCOVERY
As detailed in the clinical section of this review, PARP inhibitors selectively target HR-deficient tumors, including tumors from patients bearing hereditary BRCA1 and 2 mutations. Approximately 15% of EOC bear mutations in BRCA1 or BRCA2. 169, 170 Moreover, an elevated proportion of sporadic EOC (up to 55%)-and in particular high-grade serous EOC-are HRR deficient for a Abbreviations: bid, twice a day; C, carboplatin; CB, clinical benefit; CDDP, cisplatin; CR, complete response; DLT, dose limiting toxicity; EOC, epithelial ovarian cancer; MTD, maximal tolerated dose; NSCLC, non-small-cell lung cancer; ORR, overall response rate; OS, overall survival; OTD, optimal tolerated dose; P, paclitaxel; PARP, poly(ADP-ribose) polymerase; PD, progressive disease; PFS, progression-free survival; PID, PARP inhibitory dose; PI3K, PI3kinase; PLD, pegylated liposomal doxorubicin; PR, partial response; SD, stable disease; TTP, time to progression.
Anticancer profile of PARP inhibitors J Michels et al variety of reasons, including BRCA1 promoter methylation, MRE11 mutation and EMSY amplification. 167, [171] [172] [173] Thus, reliable biomarkers for the identification of patients with defects in the HR pathway would greatly facilitate the clinical development of PARP inhibitor-based therapies (Figure 2) .
Recently, 24 EOCs were classified as HRR-competent or HRRdeficient, based on the ability of primary tumor cells from ascitic fluid cultures to form RAD51 foci, in vitro, upon short exposure to AG014699. 174 In this study, the amount of RAD51 foci per nucleus inversely correlated with cytotoxicity of AG014699 in vitro. However, it remains unknown whether this functional marker of HRR proficiency affects therapeutic outcome in vivo. 174 In a cohort of 68 sporadic breast cancer patients, reduced in vivo formation of RAD51 foci (upon neoadjuvant anthracycline-based chemotherapy) correlated with high histological grade and intense proliferation rate (as determined by the Ki67 marker), yet was predictive of pathologic complete responses. 111 Remarkably, TNBCs, whose basal-like phenotype closely resembles that caused by BRCA mutations, constituted the subgroup of breast cancers that most frequently exhibited a low RAD51 score. However, the use of RAD51 foci as a biomarker for HRR proficiency has two major intrinsic limits that would have to be overcome in future studies. First, RAD51 foci cannot be detected at baseline and must be induced by DNA damage. Second, the expression of RAD51 is restricted to the S and G2 phases of proliferating cells, meaning that it cannot be detected in tumor cells that are dormant or arrested in the G1 phase. 111 It remains to be determined whether other types of DNA damage-elicited foci, such as Mre11 foci, 29 might yield a more accurate biomarker to predict sensitivity to PARP inhibitors than RAD51 foci.
Several studies reported that PARP1 binding protein PARPBP (also known as PARI or CI2orf48), which is overexpressed in pancreatic human carcinoma cells, 175 inhibited HRR and induced an increase in PAR levels. 176, 177 This result suggests that PARPBP might predict both HRD and sensitivity to PARP inhibition. PARP is also hyperactivated in BRCA2 mutated-and thus HRR-deficientcancer cell lines, as shown for instance for V-C8 hamster and CAPAN1 pancreatic cell lines, and this correlated with sensitivity to PARP inhibitors. 96 Furthermore, the knockdown of HRR proteins (for example, RAD54, RAD52, BLM, WRN and XRCC3) in U2OS osteosarcoma cells induced HRD, PARP hyperactivation and increased sensitivity to PARP inhibitors. 96 Indeed, high levels of PAR-modified proteins detectable by western blotting or immunohistochemistry predicted the cytotoxic response to PARP inhibitors in vitro and in vivo, in CDDP-resistant human cancers cells of different histological origins. 59 These finding suggest that immunohistochemical methods assessing the abundance of PAR in cells (which correlates with PARP activity) may be useful to predict sensitivity to PARP inhibitors (Figure 3) .
The genomic instability of HRR-deficient tumors might be used as a predictive biomarker for the response to PARP inhibitors. Predicitve biomarkers for PARP inhibitors. BRCA1/2 loss-offunction mutation impairs HRR and induces a PARP hyperactivation reflected by an increased abundance of poly(ADP)ribose polymers (PAR). HRD may occur without BRCA mutation in the context of 'BRCAness' . EMSY genes and ETS fusion genes that are reported in different tumors inhibit BRCA2. 53BP1 is a DDR factor that interacts with BRCA1 upstream of HRR and NHEJ. Concomitant 53BP1 and BRCA1 loss may reinitiate HRR and subsequent resistance to PARP inhibition. Genetic instability correlates with HRD according to a HRD score. PARPBP overexpression is reported in pancreatic cancers, inducing genetic instability and PARP hyperactivation. MRE11 from the MRN protein complex (MRE11, RAD50 and NBS1) acts at the stalled replication fork upstream of the HRR. RAD51 is one of the main effectors of HRR. Aurora A is an essential actor of mitosis and cell cycle regulation and is often overexpressed in tumors. Overexpression of Aurora A inhibits RAD51 recruitment. Apart from HRR deficiencies, two main actors of the final steps of the BER pathway may be of interest. Downregulation of polymerase b and XRCC1 may induce increased PARylation. HER2 and PARP overexpression initiate an overexpression of the transcription factor NFkB, actor of the immune response. Note that none of the depicted putative biomarkers is entirely specific for the response of tumor cells to PARP inhibitors. Aurora A, AURKA; BER, base excision repair; 53BP1, p53-binding protein-1; BRCA, breast cancer gene; CDK1, cyclin-dependent kinase 1; DDR, DNA damage response; HER2, human epidermal growth factor receptor 2; HRD score, homologous recombination deficiency score; HRR, homologous recombination; HR, homologous recombination repair; I PARP, inhibitors de PARP; MAPK, mitogen-activated protein kinase; MRE11, meiotic recombination protein 11; NF-kB, nuclear factor-kappa B; PAR, poly-(ADPribose); PARPBP, poly-(ADP-ribose) polymerase-binding protein; PLK3, polo-like kinase-3; POLB, polymerase b; XRCC1, X-ray repair cross-complementing 1. Figure 3 . PARP hyperactivation. Preclinical data report that the abundance of PAR may reflect cellular DNA repair deficiencies or DDR (red box), thus constituting a universal predictive biomarker for the response to PARP inhibitors. PAR is detectable by different methods listed in the figure. BRCA, breast cancer gene; DDR, DNA damage response; HRR, homologous recombination repair; MRE11, meiotic recombination protein 11; NAD þ , nicotinamide dinucleotide; PAR, poly-(ADP-ribose); PI3K, phosphoinositide 3-kinase; POLB, polymerase b; XRCC1, X-ray repair cross-complementing 1.
A HRD score has been defined by assessing mutations of BRCA1 and BRCA2, the methylation of their promoters, the level of expression of BRCA1 at the mRNA level, as well as LOH affecting the loci coding for BRCA1 and BRCA2. This could be validated in two independent human EOC cohorts. [178] [179] [180] However, apart from the BRCA promoter methylation, these analyses cannot detect HRR deficiencies that fall into the category of 'BRCAness', and hence must be considered as intrinsically suboptimal.
In conclusion, there is ample awareness of the urgent need of defining reliable biomarkers that predict the clinical efficacy of PARP inhibitors. The definition and practical implementation of such biomarkers is still in its infancy. However, it is our hope that constant progress in the comprehension of the complexities of DDRs will eventually lead to the development of simple and reproducible tests that facilitate the clinical application of PARP inhibitors. ABBREVIATIONS ART, ADP-ribosyl transferases; ATM, ataxia-telangiectasia mutated; BER, base excision repair; bid, twice a day; CBR, clinical benefit rate; CDDP, cisplatin; CDK1, cyclin-dependent kinase 1; DDR, DNA damage response; DiOC6(3), 3,3 0 -dihexyloxacarbocyanine iodide; DLT, dose limiting toxicity; DNA-PK, DNA-dependent protein kinase; DNA-PKcs, catalytic subunit of DNA-dependent protein kinase; DR, direct repair; DSB, double-strand break; DSBR, doublestrand break repair; EGBFr, epidermal growth factor receptor; EOC, epithelial ovarian cancer; GI, gastro-intestinal; HDAC, histone deacetylase; HzR, hazard ratio; HR, homologous recombination; HRD, homologous recombination deficiency; HRR, homologous recombinational repair; HSP90, heat-shock protein of 90 KDa; LOH, loss of heterozygosity; MAPK, mitogen-activated protein kinase; MGMT, O 6 -methylguanine DNA methyltransferase; MMR, mismatch repair; MTD, maximum tolerated dose; NAD, nicotinamide adenine dinucleotide; NER, nucleotide excision repair; NHEJ, nonhomologous end joining; NSCLC, non-small-cell lung carcinoma; ORR, overall response rate; OS, overall survival; PAR, poly-(ADPribose); PARP, poly-(ADP-ribose) polymerase; PARPBP, PARP1-binding protein; PARP I, PARP inhibitor; PLD, pegylated liposomal doxorubicin; PD, progressive disease; PFI, platinum-free interval; PFS, progression-free survival; PI, propidium iodide; PI3K, phosphoinositide 3-kinase; PS, performance status; PSA, prostatespecific antigen; PTEN, phosphatase and tensin homolog; RECIST, response evaluation criteria in solid tumors; RNAi, RNA interference; SNP, single-nucleotide polymorphism; SSB, single-strand break; SSBR, single-strand break repair; TMZ, temozolomide; TNBC, triple-negative breast cancer; XRCC1, X-ray repair cross-complementing 1
